雷米封治疗结核并HBV感染病人中HBVm变化的观察

Study on HBV Changes in Tuberculosis Patients after the Use of Rimifon Therepy

１９９１年８月～１９９３年６月我们对结核合并ＨＢＶ感染的病人经雷米封治疗后半年之内ＨＢＶｍ（乙型肝炎病毒标志物）的变化进行了观察共９５例，结果ＨＢｓＡｇ及ＨＢｅＡｇ的阴转率分别为２６．３２％和３９．１３％，抗原阴转率（两项中一项以上阴转者）为３２．６３％，肝功能未显示毒性损害。

This paper reported on changes of HBVm in tuberculosis patients who accompanied with HBV infection after the use of Rimifon therapy. The results showed that HBsAg and HBeAg negative rates were 26.32% and 29.13% respectively after the use of Rimifon therapy. The negative rates were higher than HBVm natural negative rate(10%).It suggests that Rimifon perhaps inhibiti HBV. It is worth researching continuously. The Rimifon pharmacologic actions are discussed.